Risk Factors Update Summary
- Added detailed risks related to Israel-Hamas conflict, potential economic implications, and widening conflict involving other terrorist organizations.
- Increased the valuation allowance on net deferred tax assets from $6 million to $49 million.
- Expanded on the risks related to patient enrollment in clinical trials and potential delays.
- Added risks related to the potential failure to protect intellectual property rights and challenges in trademark protection.
- Mentioned the intention to conduct substantially all operations in the U.S. for federal income tax purposes.
- Discussed the concentration of voting power among executive officers and directors, affecting decision-making.
- Addressed the lack of a formal cybersecurity risk management program and reliance on an outsourced IT consultant.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1781983&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.